TokenPost·
FDA Extends Capricor’s Deramiocel Review, Sets Nov. 22 Action Date
The amendment includes two-year Phase 3 HOPE-3 extension data and an integrated efficacy summary across HOPE-2 and HOPE-3.
More news
- TokenPostAave V4 Active Loans Top $600 Million, Above Prior $400 Million Mark
- TokenPostFive Addresses Withdraw $20.78 Million in UNI From Coinbase
- TokenPostTrader Opens $2.51 Million Anthropic Long During Post-Terms Drop
- The DefiantNvidia Falls After Report of Huang Affair With Executive
- Crypto BriefingHouse Republicans push Nvidia CEO Jensen Huang to testify over alleged spy ties
- TokenPostSouth Korean Lawmaker Calls for Scrapping Planned Crypto Gains Tax